Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas

International Journal of Developmental Neuroscience

Volumn 17, Issue 5-6, 1999, Pages 579-591

  Sasaki, M ^a,b   Wizigmann Voos, S ^a,b   Risau, W ^b   Plate, K H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Antisense; Gene therapy; Malignant gliomas; Retrovirus producer cells; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GLIOMA; MOLECULAR CLONING; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; RAT; RETROVIRUS; TUMOR GROWTH;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0032846624     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(99)00053-2     Document Type: Article

References (34)

1. Adams M.A., Ramesh N., Miller A.D., Osborne W.R. Internal initiation of translation in retroviral vectors carrying picornavirus 5′-nontranslated regions. J. Virol. 65:1991;4985-4990.
2. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 114:1992;521-532.
3. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;2745-2752.
4. Cheng S.H., Huang H.J., Nagane M., Ji X.D., Wang D., Shih C.C., Arap W., Huang C.M., Cavenee W.K. Suppression of glioblastoma angiogenecity and tumorigenecity by inhibition of endogenousexpression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 93:1996;8502-8507.
5. Conolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J., Siegel N.R., Leimgruber R.M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1989;1470-1478.
6. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
7. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
9. Keck P.J., Hauser S., Krivi G., Sanzo K., Warren T., Feder J., Conolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
10. Kendal R.L., Thomas K.A. Inhibition of vascular endothelial growth factor activity by an endogeneously encoded soluble receptor. Proc. Natl. Acad. Sci. USA. 90:1993;10705-10709.
11. Kim K.J., Li B., Winer J., Armani M., Gillet N., Philipps H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844.
12. Kleihues P., Burger P.C., Plate K.H., Ohgaki H., Cavenee W.K. Kleihues P., Cavenee W.K. Glioblastoma: Pathology and Genetics of Tumours of the Nervous System. 1997;16-24 IARC, Lyon.
13. Kong H.L., Crystal R.G. Gene therapy strategies for tumor angiogenesis. J. Nat. Can. Inst. 90:1998;273-286.
14. Kramm C.M., Sena-Esteres M., Barnett F.H., Rainov N.G., Schuback D.E., Yu J.S., Dechan P., Paulus W., Chiacca E.A., Breakfield X.O. Gene therapy for brain tumors. Brain Pathol. 5:1995;345-381.
15. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
16. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1988;1120-1124.
17. Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 252:1991;854-856.
18. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., Strawn L.M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
19. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature. 367:1994;576-579.
20. Millauer B., Wizigmann-Voos S., Schnürch H., Martinez R., Moller N.P.H., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggests flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
21. Plate K.H. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metastasis Rev. 15:1996;237-240.
22. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53:1993;5822-5827.
23. Plate K.H., Breier G., Weich H.A., Mennel H.D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer. 59:1994;520-529.
24. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
25. Plate K.H., Risau W. Angiogenesis in malignant gliomas. Glia. 15:1995;339-347.
26. Ram Z., Culver K.W., Oshiro E.M., Viola J.J., DeVroom H.L., Otto E., Long Z., Chiang Y., McGarrity G.J., Muul L.M., Katz D., Blaese R.M., Oldfield E.H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1997;1354-1361.
27. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisnse VEGF sequences. Cancer Res. 56:1996;393-401.
28. Sasaki M., Plate K.H. Gene therapy of malignant gliomas: recent advances in experimental and clinical studies. Ann. Oncol. 9:1998;1155-1166.
29. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
30. Shweiki D., Neeman M., Itin A., Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and glucose defieciency in multicell spheroids-implantations for tumor angiogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;768-772.
31. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1997;1222-1227.
32. Stratmann A., Risau W., Plate K.H. Cell type specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153:1998;1459-1466.
33. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui T.H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orifi L., Risau W., Flamme I., Ullrich A., Hirth K.P., Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3544.
34. Terman B.C., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Comm. 187:1992;1579-1586.